USPTO Patent Application: Modified Release Minoxidil Formulations

The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.

USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder

The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.

USPTO Patent Application for ABHD6 Antagonist Drug

The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.

USPTO Patent Application for Tyk2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.

USPTO Patent Application: TYK2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.

USPTO Patent Application: Upadacitinib Pharmaceutical Composition

The USPTO has published a new patent application (US20260083732A1) detailing a pharmaceutical composition for upadacitinib. The application, filed on September 6, 2023, describes a formulation involving upadacitinib, a hydrophobic release-controlling polymer, a pH modifier, and other excipients.

Uveal Melanoma Treatment Patent Application

The USPTO has published a patent application (US20260083731A1) detailing methods for treating uveal melanoma using a PKC inhibitor. The application, filed on August 25, 2023, by inventors Matthew Anthony Maurer, Michael Gabriel O'Quigley, and Julie Hambleton, focuses on neoadjuvant and/or adjuvant therapy to reduce metastasis and preserve eye function.

USPTO Patent Application: Dapiprazole for Eye Disorders

The USPTO has published a patent application (US20260083730A1) for a method of treating eye disorders using dapiprazole. The application, filed by Baradaina LLC, details a liquid composition for treating conditions such as presbyopia, glaucoma, or halos and glare.

USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells

The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.

USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections

The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.